All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
AACR 2017: Poster 1766/26 – Alterations in TP53 Mutated and wild type AML patients
On Monday 3rd April, at the 107th American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, there was an enthralling poster session focused on the “Molecular Classification of Tumors”.
Anna Ferrari from the Institute of Hematology, Bologna, Italy, and colleagues presented data from their study which investigated the frequency, types, and prognostic impact of TP53 mutations in adult Acute Myeloid Leukemia (AML) patients.
258 adult AML patients with miscellaneous cytogenetic abnormalities and Normal Karyotype (NK-AML, n = 65) were examined for TP53 mutations.
The key results were:
- Using mutation analysis, forty-eight different types of TP53 mutations (deleterious point mutations) were detected in thirty-nine patients
- TP53 mutation rate in patients was 15.1%
- Complex Karyotype (CK) reported in 71.8% of TP53 mutated patients (28/39) compared to 28.2% of TP53 mutated patients (11/39) with no CK; P > 0.0001
- TP53 alterations were significantly associated with poor Overall Survival (OS) and Event Free Survival (EFS); P < 0.0001
- Using Copy Number Analysis (CNA), 44% of TP53 mutations were observed to have concomitant deletion
- OS was not significantly lower in TP53 mutations compared to patients with mutations/deletions; P = 0.77
- Chromosomes were significantly altered in TP53 mutated patients compared to Wild-type (WT) TP53 patients
In conclusion, TP53 mutations are deleterious and significantly correlate with poor prognosis. The authors concluded by suggesting that TP53 mutations and deletion screening should be recommended for AML patients.
References